{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:55:25Z","timestamp":1781632525861,"version":"3.54.5"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-NR077290"],"award-info":[{"award-number":["RS-2023-NR077290"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-NR077290"],"award-info":[{"award-number":["RS-2023-NR077290"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-NR077290"],"award-info":[{"award-number":["RS-2023-NR077290"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastasis causes over 90% of cancer-related deaths, including melanoma. However, most anti-cancer treatments focus on reducing tumor size rather than preventing metastatic spread. Therefore, there is a need to identify robust biomarkers that can predict and inhibit metastatic progression without inducing tumor cell death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We introduce the novel concept of synthetic anti-metastasis (SAM), which builds on the idea of synthetic lethality (SL). SAM pairs are interactions whose simultaneous impairment suppresses metastasis without inducing cell death. We identified preliminary SAM pairs using somatic mutation and clinical data from The Cancer Genome Atlas (TCGA). We selected the final SAM pairs by excluding previously reported SL interactions and pairs having at least one essential gene from preliminary pairs. We validated these SAM pairs across multiple datasets and tested their clinical relevance using survival analysis and machine learning (ML). Candidate anti-metastatic drugs for melanoma were identified through LINCS-based gene signature analysis, network analysis, and literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 325 final SAM pairs from 367 preliminary pairs. We found that patients with a high number of co-impairment or -inactivation of SAM pairs showed improved overall survival and reduced metastasis. The ML model based on SAM gene features accurately distinguished primary from metastases melanoma samples (AUROC: 0.940; HR: 0.724), outperforming models built from other known melanoma metastasis-associated genes. Finally, we discovered five compounds - MLN2480, pifithrin-\u00b5, RO4929097, trametinib, and sorafenib - as potential anti-metastatic drugs for melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides SAM pairs as a novel type of biomarkers that could predict metastatic melanoma prognosis and as therapeutic targets in terms of reducing metastasis risk. Our framework to identify SAM pairs could offer a data-driven strategy to improve the prediction and discover potential treatment for melanoma metastasis through integrated genomic, transcriptomic, and pharmacogenomic analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-025-02602-4","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:24:33Z","timestamp":1769685873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutation-informed gene pairs to predict melanoma metastasis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-4118","authenticated-orcid":false,"given":"Seongsu","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-4662","authenticated-orcid":false,"given":"Younggyun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-9038","authenticated-orcid":false,"given":"Ju Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2602_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029\u201330.","DOI":"10.1002\/cncr.33587"},{"key":"2602_CR2","doi-asserted-by":"crossref","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"key":"2602_CR3","doi-asserted-by":"crossref","unstructured":"Dillek\u00e5s H, Rogers M, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8(12):5574\u20136.","DOI":"10.1002\/cam4.2474"},{"key":"2602_CR4","doi-asserted-by":"crossref","unstructured":"Braeuer RR, et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 2014;27(1):19\u201336.","DOI":"10.1111\/pcmr.12172"},{"key":"2602_CR5","doi-asserted-by":"crossref","unstructured":"Qian CN, Mei Y, Zhang J. Cancer metastasis: issues and challenges. Chin J Cancer. 2017;36(1):38.","DOI":"10.1186\/s40880-017-0206-7"},{"key":"2602_CR6","doi-asserted-by":"crossref","unstructured":"Fares J, et al. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28.","DOI":"10.1038\/s41392-020-0134-x"},{"key":"2602_CR7","doi-asserted-by":"crossref","unstructured":"Zou L, et al. Current approaches of photothermal therapy in treating cancer metastasis with Nanotherapeutics. Theranostics. 2016;6(6):762\u201372.","DOI":"10.7150\/thno.14988"},{"key":"2602_CR8","doi-asserted-by":"crossref","unstructured":"Gandalovicova A, et al. Migrastatics-anti-metastatic and anti-invasion drugs: promises and challenges. Trends Cancer. 2017;3(6):391\u2013406.","DOI":"10.1016\/j.trecan.2017.04.008"},{"key":"2602_CR9","doi-asserted-by":"crossref","unstructured":"Su W, et al. Bioinformatic analysis reveals hub genes and pathways that promote melanoma metastasis. BMC Cancer. 2020;20(1):863.","DOI":"10.1186\/s12885-020-07372-5"},{"key":"2602_CR10","unstructured":"Xie R, et al. Identification of core genes and pathways in melanoma metastasis via bioinformatics analysis. Int J Mol Sci. 202223(2)."},{"key":"2602_CR11","doi-asserted-by":"crossref","unstructured":"Liu Z, et al. Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management. Cancer Immunol Immunother. 2023;72(3):599\u2013615.","DOI":"10.1007\/s00262-022-03279-1"},{"issue":"3","key":"2602_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00262-022-03279-1","volume":"72","author":"Z Liu","year":"2023","unstructured":"Liu, Z., et al., Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management. Cancer Immunol Immunother, 2023. 72(3): p. 599-615.","journal-title":"Cancer Immunol Immunother"},{"key":"2602_CR13","doi-asserted-by":"crossref","unstructured":"Leng S, et al. Machine learning-derived identification of tumor-infiltrating immune cell-related signature for improving prognosis and immunotherapy responses in patients with skin cutaneous melanoma. Cancer Cell Int. 2023;23(1):214.","DOI":"10.1186\/s12935-023-03048-9"},{"key":"2602_CR14","doi-asserted-by":"crossref","unstructured":"O'Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18(10):613\u201323.","DOI":"10.1038\/nrg.2017.47"},{"key":"2602_CR15","doi-asserted-by":"crossref","unstructured":"Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011;10(5):351\u201364.","DOI":"10.1038\/nrd3374"},{"key":"2602_CR16","doi-asserted-by":"crossref","unstructured":"Lee JS, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell. 2021;184(9):2487\u20132502.e13.","DOI":"10.1016\/j.cell.2021.03.030"},{"key":"2602_CR17","doi-asserted-by":"crossref","unstructured":"Schaffer AA, et al. A systematic analysis of the landscape of synthetic lethality-driven precision oncology. Med. 2024;5(1):73\u201389.e9.","DOI":"10.1016\/j.medj.2023.12.009"},{"key":"2602_CR18","doi-asserted-by":"crossref","unstructured":"Lee JS, et al. Harnessing synthetic lethality to predict the response to cancer treatment. Nat Commun. 2018;9(1):2546.","DOI":"10.1038\/s41467-018-04647-1"},{"key":"2602_CR19","doi-asserted-by":"crossref","unstructured":"Lord C, Ashworth A. PARP inhibitors- Synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","DOI":"10.1126\/science.aam7344"},{"key":"2602_CR20","doi-asserted-by":"crossref","unstructured":"Markowska M, et al. Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients. Sci Rep. 2023;13(1):7049.","DOI":"10.1038\/s41598-023-34161-4"},{"key":"2602_CR21","unstructured":"Ellrott K, et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 2018;6(3):271\u201381.e7."},{"key":"2602_CR22","unstructured":"Liu J, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400\u201316.e11."},{"key":"2602_CR23","doi-asserted-by":"crossref","unstructured":"Park J, et al. Gene-wise burden of coding variants correlates to noncoding pharmacogenetic risk variants. Int J Mol Sci. 2020;21(9).","DOI":"10.3390\/ijms21093091"},{"key":"2602_CR24","doi-asserted-by":"crossref","unstructured":"Pilarczyk M, et al. Connecting omics signatures and revealing biological mechanisms with iLINCS. Nat Commun. 2022;13(1):4678.","DOI":"10.1038\/s41467-022-32205-3"},{"issue":"12","key":"2602_CR25","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 Blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916\u201327.","journal-title":"Nat Med"},{"issue":"23","key":"2602_CR26","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, et al. Genetic basis for clinical response to CTLA-4 Blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"key":"2602_CR27","doi-asserted-by":"crossref","unstructured":"Eliezer M, Van Allen DM, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Marnix H, Geukes Foppen SM, Goldinger J, Utikal JC, Hassel B, Weide KC, Kaehler C, Loquai P, Mohr, Wu J. Ralf Gutzmer, Reinhard Dummer, Stacey Gabriel, Catherine, Dirk Schadendorf, and Levi A. Garraway, Genomic correlates of response to CTLA-4 Blockade in metastatic melanoma. Science, 2015: pp. 207\u201311.","DOI":"10.1126\/science.aad0095"},{"key":"2602_CR28","doi-asserted-by":"crossref","unstructured":"Pollard J. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004:71\u20138.","DOI":"10.1038\/nrc1256"},{"key":"2602_CR29","doi-asserted-by":"crossref","unstructured":"Talmadge JE. Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin Cancer Biol. 2011;21(2):131\u20138.","DOI":"10.1016\/j.semcancer.2010.12.002"},{"key":"2602_CR30","doi-asserted-by":"crossref","unstructured":"Grant G, Ferrer CM. The role of the immune tumor microenvironment in shaping metastatic dissemination, dormancy, and outgrowth. Trends Cell Biol. 2025.","DOI":"10.1016\/j.tcb.2025.05.006"},{"key":"2602_CR31","doi-asserted-by":"crossref","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","DOI":"10.1186\/s13059-017-1349-1"},{"key":"2602_CR32","unstructured":"Itay T, Benjamin I, Sanjay MP, Marc HW, Daniel T, John J. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016:189\u201396."},{"key":"2602_CR33","doi-asserted-by":"crossref","unstructured":"Gerber T, et al. Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. Oncotarget. 2017;8:846\u201362.","DOI":"10.18632\/oncotarget.13666"},{"key":"2602_CR34","doi-asserted-by":"crossref","unstructured":"Fang Z, Liu X, Peltz G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics. 2023;39(1).","DOI":"10.1093\/bioinformatics\/btac757"},{"key":"2602_CR35","doi-asserted-by":"crossref","unstructured":"Zheng F, et al. Interpretation of cancer mutations using a multiscale map of protein systems. Science. 2021;374(6563):eabf3067.","DOI":"10.1126\/science.abf3067"},{"key":"2602_CR36","doi-asserted-by":"crossref","unstructured":"Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010;80(5):624\u201337.","DOI":"10.1016\/j.bcp.2010.04.029"},{"key":"2602_CR37","doi-asserted-by":"crossref","unstructured":"Wang AX, Qi XY. Targeting RAS\/RAF\/MEK\/ERK signaling in metastatic melanoma. IUBMB Life. 2013;65(9):748\u201358.","DOI":"10.1002\/iub.1193"},{"key":"2602_CR38","doi-asserted-by":"crossref","unstructured":"Wagstaff W, et al. Melanoma: molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance. Genes Dis. 2022;9(6):1608\u201323.","DOI":"10.1016\/j.gendis.2022.04.004"},{"key":"2602_CR39","doi-asserted-by":"crossref","unstructured":"Bailey CM, Kulesa PM. Dynamic interactions between cancer cells and the embryonic microenvironment regulate cell invasion and reveal EphB6 as a metastasis suppressor. Mol Cancer Res. 2014;12(9):1303\u201313.","DOI":"10.1158\/1541-7786.MCR-13-0673"},{"key":"2602_CR40","doi-asserted-by":"crossref","unstructured":"Yang NY, et al. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J Biol Chem. 2006;281(43):32574\u201386.","DOI":"10.1074\/jbc.M604338200"},{"key":"2602_CR41","doi-asserted-by":"crossref","unstructured":"Arora S, Scott AM, Janes PW. Eph Receptors in Cancer. Biomedicines. 2023;11(2).","DOI":"10.3390\/biomedicines11020315"},{"key":"2602_CR42","doi-asserted-by":"crossref","unstructured":"Song B, et al. Characterization of coagulation-related gene signature to predict prognosis and tumor immune microenvironment in skin cutaneous melanoma. Front Oncol. 2022;12:975255.","DOI":"10.3389\/fonc.2022.975255"},{"key":"2602_CR43","doi-asserted-by":"crossref","unstructured":"Huang B, et al. Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients. Cancer Cell Int. 2020;20:195.","DOI":"10.1186\/s12935-020-01271-2"},{"key":"2602_CR44","doi-asserted-by":"crossref","unstructured":"Luan, H., et al., Exploration and validation of metastasis-associated genes for skin cutaneous melanoma. Sci Rep, 2022. 12(1): p. 13002.","DOI":"10.1038\/s41598-022-17468-6"},{"key":"2602_CR45","doi-asserted-by":"crossref","unstructured":"Zhang L, et al. Ubiquitination-related biomarkers in metastatic melanoma patients and their roles in tumor microenvironment. Front Oncol. 2023;13:1170190.","DOI":"10.3389\/fonc.2023.1170190"},{"key":"2602_CR46","doi-asserted-by":"crossref","unstructured":"Leonard MK, et al. Identification of a gene expression signature associated with the metastasis suppressor function of NME1: prognostic value in human melanoma. Lab Invest, 2018;98(3):327\u201338.","DOI":"10.1038\/labinvest.2017.108"},{"key":"2602_CR47","doi-asserted-by":"crossref","unstructured":"Huang R, et al. The Identification of prognostic and metastatic alternative splicing in skin cutaneous melanoma. Cancer Control. 2022;29:10732748211051554.","DOI":"10.1177\/10732748211051554"},{"key":"2602_CR48","doi-asserted-by":"crossref","unstructured":"Bhalla S, et al. Prediction and analysis of skin cancer progression using genomics profiles of patients. Sci Rep. 2019;9(1):15790.","DOI":"10.1038\/s41598-019-52134-4"},{"key":"2602_CR49","doi-asserted-by":"crossref","unstructured":"Wu, X, Zhao J. Novel oxidative stress-related prognostic biomarkers for melanoma associated with tumor metastasis. Medicine (Baltimore). 2021;100(8):e24866.","DOI":"10.1097\/MD.0000000000024866"},{"key":"2602_CR50","doi-asserted-by":"crossref","unstructured":"Zhou X, et al. Integrated analysis to reveal potential therapeutic targets and prognostic biomarkers of skin cutaneous melanoma. Front Immunol. 2022;13:914108.","DOI":"10.3389\/fimmu.2022.914108"},{"key":"2602_CR51","doi-asserted-by":"crossref","unstructured":"Nurzat Y, et al. Identification of therapeutic targets and prognostic biomarkers among integrin subunits in the skin cutaneous melanoma microenvironment. Front Oncol. 2021;11:751875.","DOI":"10.3389\/fonc.2021.751875"},{"key":"2602_CR52","unstructured":"Lundberg SM, Lee SI. A unified approach to interpreting model predictions. Advances in neural information processing systems 30 (Nips 2017). 2017. p. 30."},{"key":"2602_CR53","doi-asserted-by":"crossref","unstructured":"Lamb J, et al. The Connectivity map- using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929\u201335.","DOI":"10.1126\/science.1132939"},{"key":"2602_CR54","doi-asserted-by":"crossref","unstructured":"Sirota M, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011;3(96):96ra77.","DOI":"10.1126\/scitranslmed.3001318"},{"key":"2602_CR55","doi-asserted-by":"crossref","unstructured":"Chen B, et al. Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nature Communications. 2017;8(1).","DOI":"10.1038\/ncomms16022"},{"key":"2602_CR56","doi-asserted-by":"crossref","unstructured":"Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56\u201368.","DOI":"10.1038\/nrg2918"},{"key":"2602_CR57","doi-asserted-by":"crossref","unstructured":"Menche J, et al. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347(6224):1257601.","DOI":"10.1126\/science.1257601"},{"key":"2602_CR58","doi-asserted-by":"crossref","unstructured":"Guney E, et al. Network-based in silico drug efficacy screening. Nat Commun. 2016;7:10331.","DOI":"10.1038\/ncomms10331"},{"key":"2602_CR59","doi-asserted-by":"crossref","unstructured":"Szklarczyk D, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u2013D646.","DOI":"10.1093\/nar\/gkac1000"},{"key":"2602_CR60","doi-asserted-by":"crossref","unstructured":"Davis AP, et al. Comparative toxicogenomics database's 20th anniversary: update 2025. Nucleic Acids Res. 2025;53(D1):D1328\u2013D133","DOI":"10.1093\/nar\/gkae883"},{"key":"2602_CR61","doi-asserted-by":"crossref","unstructured":"Seashore-Ludlow B, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 2015;5(11):1210\u201323.","DOI":"10.1158\/2159-8290.CD-15-0235"},{"key":"2602_CR62","doi-asserted-by":"crossref","unstructured":"Lugowska I, et al. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015;8:2251\u20139.","DOI":"10.2147\/OTT.S72951"},{"key":"2602_CR63","doi-asserted-by":"crossref","unstructured":"Wei BR, et al. Efficacy, tolerability, and Pharmacokinetics of combined targeted MEK and dual mTORC1\/2 inhibition in a preclinical model of mucosal melanoma. Mol Cancer Ther. 2020;19(11):2308\u201318.","DOI":"10.1158\/1535-7163.MCT-19-0858"},{"key":"2602_CR64","doi-asserted-by":"crossref","unstructured":"Gampa G, et al. Brain distribution and active efflux of three panRAF inhibitors: considerations in the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2019;368(3):446\u201361.","DOI":"10.1124\/jpet.118.253708"},{"key":"2602_CR65","doi-asserted-by":"crossref","unstructured":"Thippu Jayaprakash K, et al. In vitro evaluation of notch inhibition to enhance efficacy of radiation therapy in melanoma. Adv Radiat Oncol. 2021;6(2):100622.","DOI":"10.1016\/j.adro.2020.11.007"},{"key":"2602_CR66","doi-asserted-by":"crossref","unstructured":"Takeda T, et al. Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survival. Oncol Lett. 2021;22(6):827.","DOI":"10.3892\/ol.2021.13089"},{"key":"2602_CR67","doi-asserted-by":"crossref","unstructured":"Zhou Y, et al. Pifithrin-mu is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70. Oncol Rep. 2017;37(1):313\u201322.","DOI":"10.3892\/or.2016.5286"},{"key":"2602_CR68","doi-asserted-by":"crossref","unstructured":"Yang C, et al. Mapping the landscape of synthetic lethal interactions in liver cancer. Theranostics. 2021;11(18):9038\u201353.","DOI":"10.7150\/thno.63416"},{"key":"2602_CR69","doi-asserted-by":"crossref","unstructured":"Ju RJ, Stehbens SJ, Haass NK. The role of melanoma cell-stroma interaction in cell motility, invasion, and metastasis. Front Med (Lausanne). 2018;5:307.","DOI":"10.3389\/fmed.2018.00307"},{"key":"2602_CR70","doi-asserted-by":"crossref","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","DOI":"10.1016\/j.ccell.2023.02.016"},{"key":"2602_CR71","doi-asserted-by":"crossref","unstructured":"Kumar P, Ning Y, Polverini PJ. Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest. 2008;88(7):740\u20139.","DOI":"10.1038\/labinvest.2008.46"},{"key":"2602_CR72","doi-asserted-by":"crossref","unstructured":"Bunting MD, et al. Extracellular matrix proteins regulate NK cell function in peripheral tissues. Sci Adv. 2022;8(11):eabk3327.","DOI":"10.1126\/sciadv.abk3327"},{"key":"2602_CR73","doi-asserted-by":"crossref","unstructured":"Vyas, M., et al., Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells. Front Immunol, 2022. 13: p. 1098445.","DOI":"10.3389\/fimmu.2022.1098445"},{"key":"2602_CR74","doi-asserted-by":"crossref","unstructured":"Suwei, D., et al., Metformin inhibits melanoma cell metastasis by suppressing the miR-5100\/SPINK5\/STAT3 axis. Cell Mol Biol Lett, 2022. 27(1): p. 48.","DOI":"10.1186\/s11658-022-00353-5"},{"key":"2602_CR75","doi-asserted-by":"crossref","unstructured":"Hafner, C., et al., Loss of EphB6 expression in metastatic melanoma. International Journal of Oncology, 2003. 23(6): p. 1553-1559.","DOI":"10.3892\/ijo.23.6.1553"},{"key":"2602_CR76","doi-asserted-by":"crossref","unstructured":"Liu W, et al. ZFPM2-AS1 facilitates cell proliferation and migration in cutaneous malignant melanoma through modulating miR-650\/NOTCH1 signaling. Dermatol Ther. 2021;34(2):e14751.","DOI":"10.1111\/dth.14751"},{"key":"2602_CR77","doi-asserted-by":"crossref","unstructured":"Li MM. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and college of American pathologists. J Mol Diagn. 2017;19(1):4\u201323.","DOI":"10.1016\/j.jmoldx.2016.10.002"},{"key":"2602_CR78","doi-asserted-by":"crossref","unstructured":"Landrum, M.J., et al., ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res, 2018. 46(D1): p. D1062-D1067.","DOI":"10.1093\/nar\/gkx1153"},{"key":"2602_CR79","doi-asserted-by":"crossref","unstructured":"Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434\u201343.","DOI":"10.1530\/ey.17.14.3"},{"key":"2602_CR80","unstructured":"Davidson-Pilon C. Lifelines: survival analysis in python. J Open Source Softw. 20194(40)."},{"key":"2602_CR81","doi-asserted-by":"crossref","unstructured":"Wang J, et al. SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery. Database (Oxford). 2022;2022.","DOI":"10.1093\/database\/baac030"},{"key":"2602_CR82","doi-asserted-by":"crossref","unstructured":"Nichols CA, et al. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat Commun. 2020;11(1):2517.","DOI":"10.1038\/s41467-020-16399-y"},{"key":"2602_CR83","doi-asserted-by":"crossref","unstructured":"Wang, X. and M. Li, Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunol, 2019. 20(1): p. 4.","DOI":"10.1186\/s12865-018-0285-5"},{"key":"2602_CR84","doi-asserted-by":"crossref","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","DOI":"10.1093\/nar\/gkq603"},{"key":"2602_CR85","doi-asserted-by":"crossref","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","DOI":"10.1073\/pnas.0506580102"},{"key":"2602_CR86","doi-asserted-by":"crossref","unstructured":"Mootha VK, et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Gen. 2003;34:267\u201373.","DOI":"10.1038\/ng1180"},{"key":"2602_CR87","doi-asserted-by":"crossref","unstructured":"Behdenna A, et al. pyComBat, a Python tool for batch effects correction in high-throughput molecular data using empirical Bayes methods. BMC Bioinformatics. 2023;24(1):459.","DOI":"10.1186\/s12859-023-05578-5"},{"key":"2602_CR88","unstructured":"Pedregosa, F, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825\u201330."},{"key":"2602_CR89","doi-asserted-by":"crossref","unstructured":"Newman AM, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382.","DOI":"10.1038\/s41587-019-0114-2"},{"key":"2602_CR90","doi-asserted-by":"crossref","unstructured":"Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19(1):15.","DOI":"10.1186\/s13059-017-1382-0"},{"key":"2602_CR91","doi-asserted-by":"crossref","unstructured":"Heumos L, et al. Best practices for single-cell analysis across modalities. Nat Rev Genet. 2023;24(8):550\u201372.","DOI":"10.1038\/s41576-023-00586-w"},{"key":"2602_CR92","unstructured":"Lema\u00eetre G, Nogueira F, Aridas CK. Imbalanced-learn- a python toolbox to tackle the curse of imbalanced datasets in machine learning. J Mach Learn Res. 2017;18:559\u201363."},{"key":"2602_CR93","doi-asserted-by":"crossref","unstructured":"Park M, et al. Drug approval prediction based on the discrepancy in gene perturbation effects between cells and humans. EBioMedicine. 2023;94:104705.","DOI":"10.1016\/j.ebiom.2023.104705"},{"key":"2602_CR94","doi-asserted-by":"crossref","unstructured":"Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","DOI":"10.1093\/nar\/gkv007"},{"key":"2602_CR95","doi-asserted-by":"crossref","unstructured":"Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1): W90-7.","DOI":"10.1093\/nar\/gkw377"},{"key":"2602_CR96","doi-asserted-by":"crossref","unstructured":"Fernandez-Torras A, Duran-Frigola M, Aloy P. Encircling the regions of the pharmacogenomic landscape that determine drug response. Genome Med. 2019;11(1):17.","DOI":"10.1186\/s13073-019-0626-x"},{"key":"2602_CR97","doi-asserted-by":"crossref","unstructured":"Kong J, et al. Prediction of immunotherapy response using mutations to cancer protein assemblies. Sci Adv. 2024;10(38).","DOI":"10.1126\/sciadv.ado9746"},{"key":"2602_CR98","doi-asserted-by":"crossref","unstructured":"Pratt D, et al. NDEx, the network data exchange. Cell Syst. 2015;1(4):302\u201305.","DOI":"10.1016\/j.cels.2015.10.001"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02602-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:20:39Z","timestamp":1781630439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02602-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2602"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02602-4","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}